As anticipated from previous studies, tubastatin treatment led to dose-dependent downregulation of HDAC6, robust upregulation of the stress gene DDIT3, and significantly reduced cell viability in all tested GBM cells (Figure 4A–C,G–I,M–O). This evidence concerns the gene HDAC6 and glioblastoma.